brain

Overview of Glioblastoma (GBM)

  • Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults.

  • GBM is characterized as a highly malignant and treatment-resistant disease. Despite a century of research, there has been limited progress in effective treatments due to its complex nature.

  • The primary challenges in managing GBM relate to its extreme heterogeneity, influencing both patient outcomes and treatment efficacy.

Key Points on Heterogeneity

  • Definition of Heterogeneity in GBM:

    • Heterogeneity refers to the variability in tumor cells both between patients and within a single tumor over time and space.

    • A significant factor contributing to treatment difficulties is the presence of cancer stem cells which remain relatively unaffected during typical treatment regimens, leading to the persistence and recurrence of the disease.

  • Impact of Heterogeneity:

    • Treatment administered may selectively kill some tumor cells while leaving cancer stem cells unharmed, allowing for regrowth of distinct tumor cell populations.

    • Current understanding of GBM heterogeneity is limited; while it is acknowledged, our ability to fully characterize and exploit this knowledge therapeutically is still evolving.

Current Clinical Management of GBM

  • Standard Treatment Approaches:

    • Typical management includes a combination of surgical resection, radiation, and chemotherapy; however, the survival rates remain low.

    • Most patients have a life expectancy of only 8 to 9 months post-diagnosis, highlighting the need for more effective therapies.

  • Limitations in Sample Collection:

    • Clinical samples primarily come from a single biopsy, which captures a limited snapshot of the tumor. This method impairs the understanding of the tumor's overall biological behavior and its complexity.

    • Analogically, if GBM represents a forest, traditional methods only sample a single tree, missing the greater ecosystem's dynamics.

Research Challenges in GBM

  • Issues with Current Research Models:

    • Standard laboratory practices often involve culturing cancer cells from one biopsy at one point in time, which does not reflect the tumor’s heterogeneity.

    • There is a reliance on a single tissue biopsy from surgical resections, which limits understanding of tumor evolution and response to therapies over the disease's lifespan.

    • Secondary research may involve only 80% of patients receiving additional biopsies, leading to limited data availability.

Spatial Heterogeneity Challenge in Research

  • In Dr. Gillespie's lab, a new initiative called the Spatial Heterogeneity Challenge introduces innovative methods to explore GBM in its entirety.

  • Primary Goals:

    • To create a comprehensive biological and genetic map of GBM that accounts for spatial and temporal dynamics within the tumor.

Sample Processing and Analysis Process

  • Upon patient consent, cell samples are obtained post-mortem to facilitate comprehensive analysis.

  • The procedures include:

    • Sectioning the brain in a transverse plane, allowing for visualization of the tumor and adjacent areas within the anatomical context.

    • These sections are labeled and processed for further downstream analysis.

Multi-Omics Database Development

  • Current Progress:

    • As of now, 14 patients have donated tissue samples for analysis.

  • Technological Platforms Utilized:

    1. TAPE-seq (Transcriptional Activity Profiling of Epigenetic states): Identifies genetic changes at single-cell resolution.

    2. MIBI (Multiplexed Ion Beam Imaging): Complex imaging that allows for simultaneous analysis of 36 targets to map cell diversity within GBM.

    3. ATAC-seq (Assay for Transposase-Accessible Chromatin using sequencing):

    • This method identifies accessible regions of chromatin associated with gene regulation.

    1. Single Cell RNA-seq:

    • Captures transcriptional outputs at the single-cell level, distinguishing between various cell types in the tumor microenvironment.

    1. Proteomics Analysis:

    • Comprehensive profiling of protein expression in individual cells, enhancing understanding of GBM biology.

Case Study of Patient One

  • Patient Profile:

    • A female in her fifties diagnosed with GBM without systematic autopsy at the time.

  • Tumor Regions of Interest:

    • Seven regions analyzed, particularly significant are T1 (right frontal region where the tumor originated), T2, and T6, demonstrating the tumor’s infiltrative nature across cerebral hemispheres.

  • Key Findings:

    • Significant infiltration across regions, indicating advanced malignancy.

    • Predominance of neural progenitor and other benign neural cell types in early sampling (T1).

    • In T6 region, an increase in mesenchymal subtype characterized by treatment resistance was observed, correlating to worse prognosis and aggressiveness.

  • Clinical Implications:

    • The emergence of the mesenchymal subtype often coincides with upregulation of pathways related to epithelial-mesenchymal transition (EMT), indicating higher invasive potential and treatment resistance.

    • EMT upregulation represents a critical mechanism behind recurrent GBM and its resilience to therapies.

  • Additional Observations:

    • Notable interactions of coagulation pathways influencing angiogenesis as a common pattern in recurrent GBM. This facilitates the tumor's growth and may be characteristic of post-radiation changes.

Conclusion

  • The research aims to deepen understanding of glioblastoma heterogeneity and treatment resistance, providing insights into personalized treatment strategies for improved patient outcomes. The ongoing methodologies and analysis of biological specimens will yield essential data to address the challenges posed by GBM heterogeneity.